The US Food and Drug Administration (FDA) has come under fire again as the federal health agency issued its third Emergency Use Authorization (EUA) for a Covid-19 treatment since the beginning of the pandemic. This extended the authorization for Gilead’s remdesivir, which it markets as Veklury.
The European Commission has signed a €63 million contract with Gilead Sciences to deliver batches of Veklury, Gilead’s name for the antiviral remdesivir, to the EU’s 27 member states as well as the UK, starting in early August.
As the global coronavirus pandemic shows no signs of abating, the US “America first” approach to preventing and treating Covid-19 has again provoked worldwide concern.
